Background
Cristina Adriana Popa
Is TRPC6 inhibition for FSGS a trick or a treat?

This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.

Is TRPC6 inhibition for FSGS a trick or a treat?
Background
Cristina Adriana Popa
Why-dralazine?! Population risk of drug induced ...

This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?

Why-dralazine?! Population risk of drug induced vasculitis
Background
Cristina Adriana Popa
From missed opportunities to equitable access: ...

Summary of the STEPS trial which will be a twitter spaces discussion

From missed opportunities to equitable access: Can STEPS redesign the kidney transplant pathway?
Background
Cristina Adriana Popa
Searchin’ For My Lost Shaker of Salt- Targeted ...

This week, we will discuss the HIT trial- a large randomized study challenging one of the most reflexive responses in hospital medicine: see hyponatremia, fix the sodium. But what if correcting the number doesn’t change what actually matters?

Searchin’ For My Lost Shaker of Salt- Targeted Treatment of Hyponatremia
news
swapnil hiremath
NephJC Covers LBCTs at the World Congress

The NephJC editors cover the simultaneous publication from the world congress

Stop acei trial

Don't Stop Me Now!

If you missed the latest NephJC discussion, at least read the highlights here.

You gotta know when to hold’em and know when to fold’em. Review the #TenTweetNephJC for the STOP ACEi Trial, and always hold onto your ACEi.